Regencell Bioscience is a pre-revenue, early-stage bioscience company based in Hong Kong, developing a Traditional Chinese Medicine formula to treat ADHD and ASD in children. The core product is a liquid, orally administered herbal formula based on the "Sik-Kee Au TCM Brain Theory," which holds that improving blood flow to the brain can address the neurological root causes of ADHD and ASD — rather than simply managing symptoms, as mainstream medications do. The formula was developed by the company's TCM practitioner, who is also the father of the CEO. Regencell plans to commercialize the product first in Hong Kong as a registered proprietary Chinese medicine, where it could be sold over the counter without a prescription, before expanding to the U.S. and other international markets. Revenue would come primarily from product sales, with potential for IP licensing or pharmaceutical partnerships. The company must first complete larger efficacy trials, obtain regulatory approval from the Hong Kong Chinese Medicines Board, and establish manufacturing capabilities before any commercialization can begin. To date, efficacy evidence is limited to two small, uncontrolled trials. The company currently generates no revenue and funds operations entirely through capital raises, with R&D expenses running under $1M annually. Commercialization plans also include technology initiatives — integrating AI, blockchain, and cryptocurrency into a digital health platform — though these remain at the concept stage.